Skip to content

Approaching ADHD from a New Angle

More than 5 million children in the U.S., aged 4-17 years old, have been diagnosed with Attention-Deficit Hyperactivity Disorder (ADHD). The condition is characterized by inattention, hyperactivity and impulsivity.

Current prescription medications and psychosocial therapies focus on ameliorating primary symptoms. No currently approved drug treats the underlying cause of ADHD, and there is no known cure.

Our pipeline includes a Phase III-ready drug product for ADHD. Preliminary studies with patients diagnosed with ADHD and taking prescribed ADHD medication indicate that these children could benefit from the administration of our product, CM-4612.